In an important milestone for Indian dermatology research, the first-time comparative clinical study of the first-his-side to include the use of Abrositinib in the treatment of medium to severe atopic dermatitis has been published in the Cureus Journal, which is a pubmed-inflyxed international medical journal under Springer.
Dr. Mir Shahnawaz, a famous Kashmiri dermatologist and founder of Dermis Skin and Hair Clinic, is a comparative analysis of the first Indian real world of Indian real -world, which is a comparative analysis of the first Indian real -world, and the first Indian real -world analysis of cyclosis.
This groundbreaking research brings valuable clinical insights into the effectiveness and safety of these systemic remedies in the Indian population and marks one of the early Indian support of Abrositinib, a selective Jak-1 inhibitor that represents a major advancement in the treatment of chronic inflammatory skin diseases.
Dr. International recognition of Shahnawaz’s work highlights not only the increasing contribution of Kashmiri physicians to global dermatology, but also presents its research as a reference point for evidence-based management of India and beyond atopic dermatitis.